Martins, Renato
University of Washington
6 papers on CoChatORCID 0000-0001-8105-4219
Most cited papers
- Verified
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 5,419
- Verified
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 820
- Verified
Non–Small Cell Lung Cancer, Version 6.2015
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 478
- Verified
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine
Thyroid Cancer Diagnosis and TreatmentAngiogenesis and VEGF in Cancer
Cited by 470
- Verified
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Schlumberger, M. J., Elisei, R., Bastholt, L., Wirth, L. J., Martins, R. G., Locati, L. D., Jarzab, B., Pacini, F., Daumerie, C., Droz, J.-P., et al. (2009) · Journal of Clinical Oncology
Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid Surgery
Cited by 340
- Verified
Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations
Veatch, J. R., Jesernig, B. L., Kargl, J., Fitzgibbon, M., Lee, S. M., Baik, C., Martins, R., Houghton, A. M., & Riddell, S. R. (2019) · Cancer Immunology Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 89
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free